CVM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CEL-SCI Corp (CVM) is not a good buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock is trading below its prior close with weak short-term price action, bearish moving averages, no meaningful bullish proprietary signal, and fresh financial results showing worsening losses and very limited cash. I would not buy this now; the clear stance is sell/avoid until the business shows stronger financial progress and a more durable uptrend.
The chart setup is weak. Price closed at 1.37 after a sharp regular-session drop of 8.81% and remains below the prior close of 1.45. MACD histogram is positive and expanding, which is a mild near-term improvement, but RSI_6 at 38.09 is still weak/neutral and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5, showing a broader downtrend. Pivot support is 1.032, with resistance at 1.773 and 2.002, so the stock is closer to testing support than breaking out. Overall trend remains bearish despite a small momentum uptick.
["MACD histogram is above zero and expanding, indicating a small short-term momentum improvement.", "Stock-trend estimate shows a roughly 50% chance of a modest move higher over the next day/week, though the edge is weak.", "No major negative insider or hedge-fund trend was reported recently."]
["Recent Q2 GAAP EPS was -$1.35, worse than the prior quarter's -$0.68.", "Cash and cash equivalents were only $1.89 million, pointing to tight liquidity.", "The stock fell sharply in the regular session and remains in a broader bearish moving-average structure.", "Options market data shows no active sentiment signal or meaningful participation.", "No AI Stock Picker signal and no recent SwingMax signal.", "No recent congress trading data or notable politically influential buying support.", "Insiders and hedge funds are neutral, with no significant positive accumulation trends."]
Latest quarter shown: Q2 2026. Cel-Sci reported GAAP EPS of -$1.35, which worsened from -$0.68 in the previous quarter, showing deteriorating profitability. Cash and cash equivalents were $1.89 million, indicating very tight liquidity. The financial snapshot was not fully available, but the available figures point to weak operating performance and limited financial flexibility.
No analyst rating or price target trend data was provided, so there is no visible Wall Street upgrade/downgrade momentum or target revision trend to support a buy case. Based on the available information, Wall Street pros would likely lean negative due to worsening quarterly losses and tight cash, while the main pro is only the possibility of a speculative bounce; the cons clearly outweigh the pros.
